Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 19/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883902 | 0.91 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL2067028 | 0.89 | FDFT1 (0.55) | FDFT1 | |
| SCHEMBL884005 | 0.88 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL2066198 | 0.88 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL2066393 | 0.88 | FDFT1 (0.54) | FDFT1 | |
| SCHEMBL4294846 | 0.87 | FDFT1 (0.55) | FDFT1 | |
| SCHEMBL884031 | 0.87 | FDFT1 (0.58) | FDFT1 | |
| SCHEMBL2066723 | 0.85 | FDFT1 (0.57) | FDFT1 | |
| SCHEMBL884045 | 0.84 | FDFT1 (0.57) | FDFT1 | |
| SCHEMBL883945 | 0.84 | FDFT1 (0.57) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-10 | — | — | US | claimed |
| JP-2009541210-A | — | — | 2009-11-26 | — | — | JP | claimed |
| EP-2020857-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | The Regents of the University of California (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007133712-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-22 | — | — | WO | claimed |
| US-8778913-B2 | Antimicrobial compositions for treating microbial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2014-06-05 | — | — | US | disclosed |
| US-8148352-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | SERPINB1, CUTA, SRRT | FDFT1 260/4885 |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | MPO, CUTA, STING1 | FDFT1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.